Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
A phase 3 trial of Glasdegib and Azacitidine in Acute myeloid leukaemia and Leukaemia, run by Pfizer, completed.
Overview
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML is a phase 3 interventional study registered as NCT04842604 by Pfizer, with 14 participants recorded, started 2021-05-17 and reaching its primary completion in 2022-12-02. Interventions recorded: Glasdegib, Azacitidine. Conditions recorded: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia.
Linked to the drug Glasdegib because the registry names it among its interventions and Acute myeloid leukaemia and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
Shares Glasdegib, Leukaemia (all types), Azacitidine, Pfizer (incl. Seagen) and the tag pipeline.
- TrialGemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
Shares Glasdegib, Acute myeloid leukaemia and the tag pipeline.
- TrialStudy of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
Shares Leukaemia (all types), Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialStudy to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
Shares Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialPevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Shares Leukaemia (all types), Azacitidine and the tag pipeline.
- TrialA Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.